Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FCN-098 in Advanced Solid Tumors
NCT05212987Phase 1Unknown
- Sponsor
- Fochon Biosciences
- Start
- Dec 2021
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of FCN-098 in solid tumor (advanced stage), sponsored by Fochon Biosciences. Primary endpoints: Incidence of Dose-Limiting Toxicity at 28 days and Recommended Phase II Dose at 28 days. Status: unknown.
02
Drugs
FCN-098
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05212987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05212987.